GlassScriptPhysician profile
Janice A Vandeveer
NPI 1861654675
$5,573.10
in general payments reported to CMS, 2019-2025
27 companies · $612 in 2025
The $612 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $634 · 2020: $314 · 2021: $773 · 2022: $950 · 2023: $1,077 · 2024: $1,213 · 2025: $612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,864 · Education: $38.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,863.65 |
| Education | $38.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,164.95 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $864.15 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $697.78 | 2019-2025 | Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $668.31 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $465.34 | 2019-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $391.94 | 2019-2025 | Jardiance, Tradjenta |
| Janssen Pharmaceuticals, INC | $233.57 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $175.62 | 2021-2025 | |
| Pfizer INC. | $148.84 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $130.79 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $124.45 | 2022-2024 | |
| Exact Sciences Corporation | $92.20 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.19 | 2023-2024 | Xifaxan |
| Astellas Pharma US INC | $67.10 | 2019-2021 | |
| Lundbeck LLC | $38.54 | 2025 | Rexulti |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $30.38 | 2024-2025 | Rexulti |
| Avanir Pharmaceuticals, INC. | $29.57 | 2019 | |
| Esperion Therapeutics, INC. | $27.58 | 2021 | |
| Dexcom, INC. | $25.72 | 2024 | Dexcom G6 Transmitter |
| Neurocrine Biosciences, INC. | $20.58 | 2019 | |
| Phathom Pharmaceuticals, INC. | $18.14 | 2024 | Voquezna |
| Abbvie INC. | $18.07 | 2022 | |
| Daiichi Sankyo INC. | $14.57 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.10 | 2022 | |
| Amarin Pharma, INC. | $12.00 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.49 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janice Vandeveer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.